semaglutide ema European Medicines Agency to investigate link between Ozempic and rare eye disorder Off-label prescription of diabetes drug

Wegovy (semaglutide) is a GLP-1 receptor agonist licensed for chronic weight management in adults and adolescents with obesity

These improvements in energy levels typically result from several interconnected factors related to metabolic health and weight management

5-8,10 Ultimately, obesity and T2D are associated with detrimental structural changes in bone, such as decreased trabecular bone connectivity and cortical bone thickness, increasing the risk of fractures and impairing healing

Given the mechanisms of action of these kinds of drugs and the biological changes associated with Alzheimers, it makes sense to examine if these drugs can slow down the progression of the disease, Griffin said

Ozempic does decrease appetite

You can help optimize how medications like semaglutide work by doing regular physical activity and following a healthy diet